$BOLD News

Last published 1mo ago

1mo agoBOLD OPCH PCRX RXOAre OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?PR NewswireInsiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to
1mo agoBOLDSerapha Bio Appoints Kenneth T. Mills as Chief Executive Officer and Names Senior Leadership Team to Advance Potential Best-in-Class in vivo Base Editing Program for Alpha-1 Antitrypsin DeficiencyGlobeNewswire- Daphne Karydas appointed as President and Chief Financial Officer - Weston Miller, MD, appointed as Chief Medical Officer - Additional appointments: Nina Hunter, PhD, as Chief Development Officer and Shiva G.
2mo agoBOLDCallio Therapeutics Appoints Zachary Hornby as Chief Executive OfficerGlobeNewswireVeteran biotech executive to lead company growth as it advances multiple dual-payload ADCs through clinical development for people living with cancer Piers Ingram, PhD, Co-Founder, transitions to Senior Advisor and
4mo agoNTHI BOLD BLZE HSCSThese Emerging Companies Are Racing Toward Major CatalystsGlobeNewswireDENVER, June 23, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological
4mo agoBOLDBoundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private PlacementGlobeNewswireCombined company to operate as Serapha Bio and to advance Serapha’s potential best-in-class in vivo base editing program for Alpha-1 Antitrypsin Deficiency Serapha’s lead program SERP-01 targets the SERPINA1 E342K
4mo agoONNVF AZN APRE BOLD+1Next-Generation DNA Repair Therapies Open New Frontiers in OncologyGlobeNewswireAUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which
6mo agoBOLDBoundless Bio Reports First Quarter 2026 Financial Results and Business HighlightsGlobeNewswireEnrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provides runway through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE)
6mo agoBOLDBoundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual MeetingGlobeNewswireSAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with
8mo agoBOLDBoundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsGlobeNewswireKOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, March
8mo agoBOLDBoundless Bio to Participate in the Leerink Global Healthcare ConferenceGlobeNewswireSAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with
8mo agoCMPX MRK SGEN PFE+8Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsightPR NewswireThe biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing...
9mo agoBOLDBoundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewswireSAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with
9mo agoBOLDBoundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash RunwayGlobeNewswireBBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026 Portfolio prioritization, including discontinuation of POTENTIATE trial, extends operating runway into the second
11mo agoBOLDBoundless Bio to Participate in the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswireSAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Boundless Bio, (NASDAQ:BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with
1y agoBOLDBoundless Bio Reports Third Quarter 2025 Financial Results and Business HighlightsGlobeNewswireEnrollment ongoing in BBI-355 / BBI-825 combination arm of the POTENTIATE trial Investigational new drug submission for BBI-940 on track, with a first-in-human clinical trial expected to initiate in the first half
1y agoBOLDBoundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewswireSAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Boundless Bio, (NASDAQ:BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with
1y agoBOLDBoundless Bio Reports Second Quarter 2025 Financial Results and Business HighlightsGlobeNewswireBBI-355 and BBI-825 combination arm of the POTENTIATE trial is now open for enrollment BBI-940 is on track for submission of an investigational new drug application in the first half of 2026 $127
1y agoBCAX BCYC BOLDRice Biotech Launch Pad welcomes Carolyn Ng to external advisory boardPR NewswireThe Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of Rice University's health and medical technology...
1y agoBOLDBoundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceGlobeNewswireSAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with
1y agoBOLDBoundless Bio Announces Portfolio Prioritization and Runway ExtensionGlobeNewswirePortfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program Operating runway extended into the first half of 2028, through
1y agoBOLDBoundless Bio Reports First Quarter 2025 Financial Results and Business HighlightsGlobeNewswireInitial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025 Novel Kinesin program on track for mid-2025
1y agoBOLDBoundless Bio to Participate in the Needham Virtual Healthcare ConferenceGlobeNewswireSAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with
1y agoBOLDBoundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business HighlightsGlobeNewswireBBI-355 Phase 1/2 POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data expected in the second half of 2025 Novel Kinesin program progressing toward development
1y agoBOLDBoundless Bio to Participate in the Leerink Global Healthcare ConferenceGlobeNewswireSAN DIEGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with
1y agoBOLDBoundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical OfficerGlobeNewswireSAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with
1y agoBOLDBoundless Bio Announces Pipeline and Leadership UpdatesGlobeNewswireCompany elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial Third ecDTx program advancing, with plans for development candidate nomination by mid-2025 Operating runway extended into 2027,
1y agoBOLDBoundless Bio to Participate in the Piper Sandler Healthcare ConferenceGlobeNewswireSAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with
2y agoBOLDBoundless Bio Reports Third Quarter 2024 Financial Results and Business HighlightsGlobeNewswireEnrollment progressing in BBI-355 POTENTIATE and BBI-825 STARMAP clinical trials, with initial proof-of-concept data expected in the second half of 2025 Cash position of $167 million, with operating runway into the
2y agoBOLDBoundless Bio to Participate in the 2024 Guggenheim Global Healthcare ConferenceGlobeNewswireSAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with
2y agoBOLDBoundless Bio Announces Departure of Chief Financial OfficerGlobeNewswireSAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with
2y agoBOLDBoundless Bio to Participate in the 2024 Cantor Global Healthcare ConferenceGlobeNewswireSAN DIEGO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with
2y agoBOLDBoundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial ResultsGlobeNewswireBBI-355 POTENTIATE clinical trial ongoing with initiatives implemented to expedite enrollment in combination cohorts; initial proof-of-concept data now expected in the second half of 2025 BBI-825 STARMAP clinical trial
2y agoBOLDBoundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceBusiness WireBoundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers,
2y agoBOLDBoundless Bio Reports First Quarter 2024 Financial Results and Corporate HighlightsBusiness WireBBI-355 Phase 1/2 POTENTIATE clinical trial ongoing; initiated targeted therapy combinations in patients with tumors with EGFR or FGFR oncogene amplifications First patient dosed in Phase 1/2 STARMAP clinical trial of
2y agoBOLDBoundless Bio to Present at the Citizens JMP Life Sciences Conference 2024Business WireBoundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers,
2y agoMRNA BOLD IBRX MGNXBiotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050PR NewswireUSA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of...
2y agoBOLDBoundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene AmplificationsBusiness WireSTARMAP (Study Treating Acquired Resistance: MAPK Amplifications) is a first-in-human, 3-part, Phase 1/2 study of BBI-825 as a single agent and in combination with select targeted cancer therapies BBI-825 is a novel,
2y agoBOLDBoundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024Business WireFindings support the ongoing development of BBI-355, a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) in Phase 1/2 development, as a differentiated treatment approach for ecDNA-enabled oncogene amplified
2y agoBOLDBoundless Bio Announces Pricing of Initial Public OfferingBusiness WireBoundless Bio, Inc. (NASDAQ:BOLD), a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified
3y agoCDTX ELVN IMPL PEAR+55AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough ScienceGlobeNewswireSAN FRANCISCO and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- 5AM Ventures is pleased that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment of candidemia
6y agoBA GOOGL JPM BMY+3Biotech Analysts See Deals, Drug Data Carrying 2020 PerformanceBloombergBiotechnology analysts expect another strong performance in 2020 after stocks rose almost 25% this year.
6y agoMBRX BOLD OTLK AXSM+1Biotechs Move Forward Developing Latest Targeted Therapies for Acute Myeloid LeukemiaPR NewswireSo it is not surprising that there is a lot of money and research resources being devoted to find new therapies for Acute Myeloid Leukemia (AML),...
6y agoBOLDAstellas Enters into Definitive Agreement to Acquire Audentes TherapeuticsBusiness WireTOKYO & SAN FRANCISCO--(BUSINESS WIRE)--Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Audentes Therapeutics, Inc. (NASDAQ: BOLD, Chairman and CEO: Matthew R. Patterson, “Audentes”), today announced that they have entered into a definitive agreement for Astellas to acquire Audentes at a price of US$60.00 per share in cash, representing a total equity val ...
6y agoBOLDAudentes Therapeutics to Participate in Upcoming Investor ConferencesBusiness WireSAN FRANCISCO--(BUSINESS WIRE)--Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced that Natalie Holles, President and Chief Operating Officer, will participate in the following investor conferences in December:
7y agoBOLDAudentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate UpdateBusiness WireSAN FRANCISCO--(BUSINESS WIRE)--Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today reported its financial results for the third quarter ended September 30, 2019, and provided an update on the company’s recent achievements and anticipated upcoming miles ...
7y agoBOLDAudentes Therapeutics to Release Third Quarter 2019 Financial Results and Provide Corporate Update on Thursday, November 7, 2019Business WireSAN FRANCISCO--(BUSINESS WIRE)--Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, will host a conference call and webcast to report its third quarter 2019 financial results and provide a corporate update on Thursday, November 7, 2019.
7y agoBOLDAudentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy (XLMTM), at the 24th International Annual Congress of the World Muscle SocietyBusiness WireSAN FRANCISCO--(BUSINESS WIRE)--Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced new positive data from ASPIRO, the clinical trial evaluating AT132 in patients with X-Linked Myotubular Myopathy (XLMTM). The data are being presented today at ...
7y agoBOLDAudentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireSAN FRANCISCO--(BUSINESS WIRE)--Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, announced it has granted equity awards that were previously approved by the Compensation Committee of its Board of Directors under the Audentes Therapeutics, Inc. 2018 Equity ...
7y agoBOLDAudentes Therapeutics to Participate in Upcoming Investor ConferencesBusiness WireSAN FRANCISCO--(BUSINESS WIRE)--Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced that Natalie Holles, President and Chief Operating Officer, will participate in the following investor conferences in October:
7y agoBOLDAudentes Announces Upcoming Presentations at the 24th International Annual Congress of the World Muscle Society, Including New Data From ASPIRO, the Clinical Trial Evaluating AT132 in Patients With X-Linked Myotubular Myopathy (XLMTM)Business WireSAN FRANCISCO--(BUSINESS WIRE)--Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced its planned presentations at the 24th International Annual Congress of the World Muscle Society in Copenhagen, Denmark, including new data from ASPIRO, the cli ...